Association Between EGF, TGF-β1, VEGF Gene Polymorphism and Colorectal Cancer

Up to the present, EGF 61 A/G, TGF-beta 1 -509 T/C, and VEGF 936 T/C gene polymorphisms have been analyzed in other cancer entities than colorectal cancer. We have now investigated the frequency of these gene polymorphisms among colorectal cancer patients. A total of 157 colorectal cancer patients and 117 cancer-free healthy people were recruited at the Surgical Department of the Universitatsklinikum Mannheim. All patients and healthy people are Caucasians. Genomic DNA was isolated from peripheral blood, and gene polymorphisms were analyzed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). The distribution of EGF 61 G/G homozygotes among colorectal cancer patients was more frequent than that in the control group (33.1% versus 11.1%; Odds Ratio [OR] = 3.962; 95% Confidence Interval [CI] = 2.036-7.708). The frequency of the "G" allele in the colorectal cancer patient group was also higher than that in the control group (51.3% versus 33.3%; OR = 2.105; 95% CI = 1.482-2.988). No difference could be found for the TGF-beta 1 and VEGF genotypes among colorectal cancer patients and healthy controls. The EGF 61 G/G genotype and the G allele are significantly related to colorectal cancer. The TGF-beta 1 -509 T/C and VEGF 936 T/C gene polymorphisms are not related to colorectal cancer.